Bliss GVS Pharma's Q3 FY 2025-26 Quarterly Results
- 11 Feb 2026
Result Summary
- Bliss GVS Pharma Ltd reported a 10.5% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 4.9%.
- Its expenses for the quarter were down by 13.7% QoQ and up 2.1% YoY.
- The net profit decreased 13.3% QoQ and decreased 4.0% YoY.
- The earnings per share (EPS) of Bliss GVS Pharma Ltd stood at 2.14 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 236.71 | 264.58 | 225.68 | -10.5% | 4.9% |
Total Expenses | 193.30 | 223.94 | 189.26 | -13.7% | 2.1% |
Profit Before Tax | 40.90 | 40.63 | 36.42 | 0.7% | 12.3% |
Tax | 16.12 | 12.04 | 10.62 | 33.9% | 51.8% |
Profit After Tax | 24.78 | 28.59 | 25.80 | -13.3% | -4.0% |
Earnings Per Share | 2.14 | 2.54 | 2.27 | -15.7% | -5.7% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Bliss GVS Pharma Ltd is a pharmaceutical company that operates primarily in the healthcare sector. It specializes in the development, manufacturing, and marketing of a wide range of pharmaceutical products. The company's product portfolio includes formulations in various therapeutic categories such as anti-malarials, antibiotics, anti-fungals, and anti-inflammatory drugs, among others. Bliss GVS Pharma has a significant presence in both domestic and international markets, with a focus on emerging markets. As of the data available up to October 2023, no specific recent major developments have been identified for the company.
Revenue
In the third quarter of fiscal year 2026, Bliss GVS Pharma Ltd reported a total income of ₹236.71 crores. This represents a decrease of 10.5% from the previous quarter's total income of ₹264.58 crores. However, when compared to the same quarter in the previous year (Q3FY25), where the total income was ₹225.68 crores, there is an increase of 4.9%. This year-over-year increase suggests a growth in revenue compared to the prior year's performance, despite a decline from the immediate preceding quarter.
Profitability
The company's profitability metrics indicate a mixed performance. Profit Before Tax (PBT) for Q3FY26 stood at ₹40.90 crores, reflecting a slight quarter-over-quarter increase of 0.7% from ₹40.63 crores in Q2FY26. On a year-over-year basis, PBT increased by 12.3% from ₹36.42 crores in Q3FY25. However, Profit After Tax (PAT) for Q3FY26 was ₹24.78 crores, which represents a decrease of 13.3% from ₹28.59 crores in the previous quarter and a 4.0% decline from ₹25.80 crores in Q3FY25. The tax expense for Q3FY26 was ₹16.12 crores, showing a significant increase both quarter-over-quarter (33.9%) and year-over-year (51.8%). Earnings Per Share (EPS) was ₹2.14, down from ₹2.54 in the previous quarter and ₹2.27 in the same quarter of the previous year, reflecting declines of 15.7% QoQ and 5.7% YoY.
Operating Metrics
Bliss GVS Pharma Ltd's total expenses for Q3FY26 were ₹193.30 crores, which is a decrease of 13.7% from ₹223.94 crores in Q2FY26. When compared to Q3FY25, where total expenses were ₹189.26 crores, there is a 2.1% increase. The decrease in expenses quarter-over-quarter aligns with the decrease in total income, suggesting cost adjustments in line with revenue fluctuations. The company's operating metrics indicate careful management of expenses despite changes in income levels, with a focus on maintaining profitability amidst varying tax obligations and market conditions.